Phase 1 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People with small cell lung cancer (SCLC) that has spread or cannot be surgically removed, where the cancer has continued to grow or worsened after at least one previous treatment (including a platinum-based chemotherapy, unless that type of treatment was not suitable for them) — previous DLL3-targeted therapy is also permitted
• People in the dose-finding stage of the trial with a type of lung cancer called large cell neuroendocrine carcinoma (LCNEC), where the cancer has progressed or was not tolerated after at least one previous treatment including platinum-based chemotherapy (unless that treatment was not suitable for them)
• People in the expansion stage of the trial with a specific type of prostate cancer that has neuroendocrine features (NEPC), confirmed by laboratory testing, who have at least one measurable tumour that shows uptake of a special imaging agent on a specific type of scan (SPECT/CT) as assessed by the investigator — prior PSMA-targeted or lutetium-177-based treatments are permitted
• People in the expansion stage of the trial with a cancer of the gut or pancreas with neuroendocrine features (GEP-NEC) that has spread or cannot be removed surgically, where the cancer progressed after at least one prior treatment including platinum-based chemotherapy (unless not suitable), and who have at least one measurable tumour showing uptake on the specific imaging scan as assessed by the investigator
• People joining the expansion stage of the trial should have received no more than two prior lines of treatment overall

Who may not be able to join:

• People whose blood counts are too low — specifically, low white blood cell levels, low haemoglobin (a measure of red blood cells), or low platelet levels
• People with a specific type of irregular heart rhythm measurement (a prolonged QTcF interval of 470 milliseconds or more) on a heart tracing (ECG)
• People whose kidneys are not working well enough, based on a specific calculation of kidney function (confirm with trial site)
• People with bladder or urinary tract blockages that cannot be managed, or with urinary incontinence that cannot be controlled
• People who have cancer that has spread to the lining around the brain or spinal cord, or who have brain metastases causing symptoms or requiring local treatment
• People with a history of, or current, significant lung inflammation or scarring (interstitial lung disease or pneumonitis of Grade 2 or higher)
• People who have previously received DLL3-targeted therapy (unless they have SCLC) or prior radioligand therapy (unless they have NEPC)

Important: Always verify eligibility with the trial site directly before applying.